Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

Now Viewing

EP: 1.Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

EP: 2.Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

EP: 3.Breaking Down Treatment Developments in Breast and Genitourinary Cancers From ESMO 2022: Drs O'Shaughnessy and Choueiri

OncLive^® will be LIVE with OncLive^® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Today-

We are reporting from the 2022 ESMO Congress!

Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Dr Hope Rugo to discuss some new data in breast cancer and Dr Ghassan Abou-Alfa to highlight some of the pivotal studies he is most excited about in gastrointestinal cancer.

Welcome to OncLive News Network! I’m Caroline Seymour.

In hormone receptor–positive, HER2-negative metastatic breast cancer, treatment with sacituzumab govitecan improved median overall survival at 14.4 months vs 11.2 months with treatment of physician’s choice. Moreover, the objective response rate, global health status and quality of life, and fatigue were improved vs treatment of physician’s choice.

In the phase 3 MONARCH 3 trial, a numerical improvement was reported with abemaciclib plus a nonsteroidal aromatase inhibitor placebo vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

RLY-4008, the first highly selective, potent FGFR2 inhibitor demonstrated potent efficacy across all doses evaluated in the phase 1/2 ReFocus trial in patients with FGFR2-altered cholangiocarcinoma. Moreover, no grade 4/5 treatment-related adverse effects were observed.

Finally, results from the KRYSTAL-1 trial indicated that adagrasib was well tolerated as monotherapy and in combination with cetuximab in heavily pretreated patients with KRAS G12C–mutated CRC, leading to an ORR of 19% and 46%, respectively. 

Please be sure to check out more of our coverage from the 2022 ESMO Congress at OncLive.com.

That’s all for today. Tomorrow, we’ll sit down with Drs Ursula Matulonis, Solange Peters, and Yelena Janjigian, who will share their perspectives on breaking research in gynecologic, lung, and gastrointestinal cancers.

Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.